310 related articles for article (PubMed ID: 36605427)
1. Clinical efficacy of combination therapy of an immune checkpoint inhibitor with taxane plus platinum versus an immune checkpoint inhibitor with fluorouracil plus platinum in the first-line treatment of patients with locally advanced, metastatic, or recurrent esophageal squamous cell carcinoma.
Li Y; Ji Y; Shen L; Yin X; Huang T; Deng B; Guo H; Wu Y; Chen Y
Front Oncol; 2022; 12():1015302. PubMed ID: 36605427
[TBL] [Abstract][Full Text] [Related]
2. Retrospective study of the combination of TP and PF regimens with or without immune checkpoint inhibitors for the first-line treatment of locally advanced or advanced esophageal squamous cell carcinoma.
Zhang Z; Yang L; Wang D; Ruan Y; Zhang J; Zhao L; Yang L; Lou C
Ther Adv Med Oncol; 2023; 15():17588359231169981. PubMed ID: 37188111
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
Li D; Tang L; Hu J; Cao X; He Y
J Cancer Res Clin Oncol; 2023 Mar; 149(3):933-939. PubMed ID: 35751682
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis.
Noori M; Mahjoubfar A; Azizi S; Fayyaz F; Rezaei N
Int Immunopharmacol; 2022 Dec; 113(Pt A):109317. PubMed ID: 36252494
[TBL] [Abstract][Full Text] [Related]
5. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis.
Zhao J; Zhang S; Guo X; Li C; Yang B; Qu X; Wang S
BMC Cancer; 2023 Dec; 23(1):1221. PubMed ID: 38082441
[TBL] [Abstract][Full Text] [Related]
6. Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.
Jing SW; Zhai C; Zhang W; He M; Liu QY; Yao JF; Wang R; Tian ZQ; Wang J; Liu JF
Front Immunol; 2022; 13():970534. PubMed ID: 36275724
[TBL] [Abstract][Full Text] [Related]
7. Comparison of neoadjuvant nab-paclitaxel plus immunotherapy versus paclitaxel plus immunotherapy for esophageal squamous cell carcinoma.
Yang Y; Li H; Chen X; Qin J; Li Y; Shen Y; Zhang R; Kang X; Wang Z; Zheng Q; Luo P; Li Y; He J
Thorac Cancer; 2023 Mar; 14(7):700-708. PubMed ID: 36788648
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.
Lu Y; Wang W; Wang F
Front Immunol; 2023; 14():1171671. PubMed ID: 37205107
[TBL] [Abstract][Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of first-line chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis.
Ma SX; Zhou T; Huang Y; Yang YP; Zhan JH; Zhang YX; Zhang ZH; Zhao YY; Fang WF; Ma YX; Chen LK; Zhao HY; Zhang L
Ann Transl Med; 2018 Jun; 6(11):201. PubMed ID: 30023364
[TBL] [Abstract][Full Text] [Related]
12. The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies.
Wang T; Yu J; Liu M; Chen Y; Zhu C; Lu L; Wang M; Min L; Liu X; Zhang X; Gubat JA; Chen Y
Drug Des Devel Ther; 2019; 13():539-553. PubMed ID: 30787595
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of immune checkpoint inhibitors versus chemotherapy in the second-line treatment of advanced esophageal squamous cell carcinoma: a meta-analysis and systematic review.
Zhu K; Chen H; Xu C; Chen D; Jin Z; Ren S; Witharana P; Chen B; Shen J
J Thorac Dis; 2023 Mar; 15(3):1186-1195. PubMed ID: 37065572
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors combined with or without radio(chemo)therapy for locally advanced or recurrent/metastatic esophageal squamous cell carcinoma.
Zhao XH; Gao HM; Wen JY; Wang HS; Wu LY; Song CY; Deng WZ; Zhu SC; Shen WB
Discov Oncol; 2023 Sep; 14(1):165. PubMed ID: 37665394
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.
Chen R; Hou X; Yang L; Zhao D
Thorac Cancer; 2019 Apr; 10(4):607-623. PubMed ID: 30734504
[TBL] [Abstract][Full Text] [Related]
16. Optimal first-line treatment for platinum-eligible metastatic urothelial carcinoma: Comparison of chemo-immunotherapy, immunotherapy, and chemotherapy- A systematic review and meta-analysis.
Li H; Ni M; Xue C; Li L; Huang R; Yang W; Hu A; An X; Shi Y
Clin Immunol; 2022 Mar; 236():108927. PubMed ID: 35031491
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of first-line treatments with immune checkpoint inhibitors plus chemotherapy for non-squamous non-small cell lung cancer: a meta-analysis and indirect comparison.
Shi Y; Chen W; Li C; Zhang Y; Bo M; Qi S; Li G
Ann Palliat Med; 2021 Mar; 10(3):2766-2775. PubMed ID: 33549014
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
19. Triple combination of HAIC-FO plus tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Tan Z; Zhang J; Xu L; Wang H; Mao X; Zou R; Wang Q; Han Z; Di Z; Wu D
PLoS One; 2023; 18(10):e0290644. PubMed ID: 37844117
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review.
Xu J; Bai Y; Li E; Xu N; Shi D; Qian J
Expert Rev Anticancer Ther; 2022 Sep; 22(9):981-998. PubMed ID: 35950848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
